ClinicalTrials.Veeva

Menu

COVID-19 : Pulmonary Ultrasound in Primary Care (ECHOVID-MG)

G

Geprovas

Status

Completed

Conditions

Ultrasound Therapy; Complications
Covid19
Pulmonary Infection
Respiratory Infection

Study type

Observational

Funder types

NETWORK

Identifiers

NCT05226403
2020-A01225-34

Details and patient eligibility

About

COVID-19 infection are characterized by fever and signs of acute respiratory infection. A worsening of respiratory symptoms that can lead to respiratory failure. The decompensation can then be brutal and require rapid recourse to respiratory assistance. The contribution of clinical examination (auscultation and monitoring of oxygen saturation in particular) remains unsatisfactory in predicting an unfavorable course. The interest of pulmonary ultrasound is known in the management of pulmonary infections. However, estimating the severity of lung damage at an early stage could be of great help in monitoring and caring for patients. Ultrasound could meet this need in general practice, the chest scanner is often unavailable in these situations.

Ultrasound signs are associated with severe forms. The contribution of pulmonary ultrasound seems particularly interesting in the context of the reassessment of patients during the worsening phase of symptoms (D5-D10).

Estimate the prevalence of ultrasound signs in patients with an acute respiratory infection suspected or confirmed to be COVID-19, at the time of the worsening phase (between D5 and D10 of the onset of symptoms).

The prevalence of ultrasound lung lesions under COVID-19 may be essential to consider the development of the ultrasound tool in primary care. Indeed, if the contribution of ultrasound is now recognized in intensive care or emergency, its place in general medicine still raises questions.

Enrollment

38 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients over 18 years of age with :

    • a clinical symptomatology suggesting an acute respiratory infection linked to COVID-19 defined by the following two categories of symptoms:

      • Sudden fever (or a feeling of fever)
      • Respiratory signs (cough, dyspnea, chest tightness) Or
    • an acute respiratory infection confirmed to COVID-19 by the result of RT-PCR screening tests.

  2. And presenting, at the time of inclusion between the 5th and 10th day of infection, one of the respiratory signs of severity felt:

    • Dyspnea, shortness of breath or difficulty in breathing
    • Chest pain or tightness

Exclusion criteria

  1. The presence of a severe form during the initial consultation. A severe form is defined by the presence of the following signs:

    • Polypnea> 22 / min
    • systolic BP <90 mmHg
    • Sp02 <90%
    • Altered consciousness, confusion, drowsiness
    • Dehydration
    • Alteration of the general condition in the elderly
  2. The presence of acute respiratory signs clearly having a cause other than a COVID-19 infection.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems